Proton Pump Inhibitors Market to Grow with a CAGR of 4.72% through 2029
Expanding acceptance of innovative drug delivery and Growing
focus on combination therapies is expected to drive the Global Proton Pump
Inhibitors Market growth in the forecast period, 2025-2029
According to TechSci Research report, “Proton Pump
Inhibitors Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2029”, the Global Proton Pump Inhibitors
Market stood at USD 3.08 billion in 2023 and is anticipated to reach 4.04 billion in the forecast period with a CAGR of 4.72% through
2029.
The utilization of proton pump inhibitors (PPIs) has been subject to scrutiny due to concerns regarding their potential association with an increased risk of COVID-19 infection and poorer outcomes in affected individuals. This scrutiny momentarily impacted the market as patients on PPI therapy were advised to reduce their medication usage. However, as the pandemic wanes and infection rates decrease, the market is expected to regain momentum during the forecast period. Proton pump inhibitors remain the primary treatment for gastroesophageal reflux disease (GERD), and their use continues to rise due to the growing prevalence of GERD and the increasing adoption of novel drug delivery systems.
Several risk factors contribute to the prevalence of GERD, including aging, obesity, altered dietary habits, and lifestyle choices. According to the World Health Organization's October 2022 data, the global population of individuals aged 60 and above is projected to double to 2.1 billion by 2050. As the elderly population is more susceptible to GERD, the utilization of proton pump inhibitors is expected to surge in tandem with the aging population, further driving market expansion. The Proton Pump Inhibitors (PPIs) industry plays a pivotal role in addressing gastrointestinal disorders and related conditions. PPIs are a class of medications widely prescribed for managing conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome, among others. They work by inhibiting the production of stomach acid, providing relief to patients suffering from acid-related disorders. The industry's growth is primarily driven by the increasing prevalence of GERD and related disorders.
Factors such as aging populations, changing dietary habits, obesity, and a rise in risk factors associated with gastrointestinal disorders contribute to the expanding demand for PPIs. Additionally, the rise in awareness about these medications and advancements in drug delivery systems further stimulate market growth. However, the industry faces challenges, including concerns regarding long-term PPI usage and the emergence of generic competitors. Nevertheless, these challenges are mitigated by the high efficacy and widespread use of PPIs, as they continue to be a cornerstone in the management of acid-related diseases. The impact of PPI usage on COVID-19 risk has garnered attention, affecting market dynamics. Despite these temporary setbacks, the industry is poised for growth, supported by the global need for effective acid-suppressing therapies. As a key player in the pharmaceutical sector, the PPI industry is expected to maintain its significance in the healthcare landscape, meeting the demands of patients with gastrointestinal disorders worldwide.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Proton Pump Inhibitors Market”
The Global Proton Pump Inhibitors Market is segmented
into By drug type, disease allocation, application, Region, and company.
Based on the drug type, Esomeprazole, a proton pump
inhibitor (PPI), has emerged as the fastest-growing segment in the global PPI
market due to several key factors. Esomeprazole belongs to the newer generation
of PPIs, known for their superior efficacy and fewer drug interactions compared
to earlier PPIs. The rapid expansion of this segment is attributed to the
following reasons: Esomeprazole has demonstrated exceptional acid-suppressing
capabilities, making it highly effective in managing acid-related disorders
such as GERD and peptic ulcers. Its safety profile and reduced drug
interactions have made it a preferred choice for both healthcare providers and
patients.
Esomeprazole enjoyed patent protection, which allowed
the manufacturer to maintain exclusivity over the drug for an extended period.
This prevented the entry of generic versions into the market, contributing to
its robust growth.
Esomeprazole is indicated for various conditions,
including GERD, peptic ulcers, and Zollinger-Ellison syndrome, making it a
versatile treatment option for healthcare professionals. Its diverse
applications have expanded its market reach. Patients have increasingly
expressed a preference for Esomeprazole due to its effectiveness, minimal side
effects, and the convenience of once-daily dosing, which enhances treatment
adherence. Ongoing research and development efforts have led to new
formulations and delivery methods for Esomeprazole, further enhancing its
appeal to patients and healthcare providers. In summary, the rapid growth of
the Esomeprazole segment is driven by its superior efficacy, safety, wide range
of indications, patient preference, and ongoing innovations. As a result,
Esomeprazole has established itself as a prominent player in the global PPI
market and is expected to continue its rapid expansion in the coming years.
Based on the application, The hospital segment has
emerged as the fastest-growing sector in the global Proton Pump Inhibitors
(PPIs) market, with several factors contributing to its rapid expansion.
Hospitals play a pivotal role in the administration of PPIs due to their
ability to manage complex and severe cases of acid-related disorders. Here are
the key reasons for the hospital segment's exceptional growth: Hospitals cater
to patients with severe or complicated gastroesophageal reflux disease (GERD),
peptic ulcers, and other acid-related disorders. These cases often require
intensive care, and PPIs are a critical component of their treatment regimens. Many
patients with acid-related disorders require inpatient care, particularly those
with complications such as bleeding ulcers or severe GERD. Hospitals are
equipped to provide round-the-clock medical attention, making them the primary
location for managing such cases.
Hospitals frequently perform procedures related to
acid-related disorders, such as endoscopies and surgeries. PPIs are routinely
prescribed before and after these procedures to reduce acid production and
promote healing. Hospitals have access to specialized medical professionals,
including gastroenterologists and surgeons, who are experts in diagnosing and
treating acid-related disorders. Their expertise contributes to the optimal use
of PPIs. Patients with acute complications of acid-related disorders, such as
severe gastrointestinal bleeding, often require immediate medical attention and
interventions. Hospitals are equipped to handle such emergencies and promptly
administer PPIs. Hospitals purchase medications in bulk, leading to cost
efficiencies. This can benefit pharmaceutical companies as they negotiate
supply contracts, fostering the growth of the hospital segment.
Hospitals are active participants in clinical trials
and research related to acid-related disorders and PPIs. These endeavors drive
awareness, adoption, and the use of PPIs within hospital settings. In summary,
the hospital segment's rapid growth in the global PPI market is attributed to
its role in managing complex medical cases, performing surgical procedures,
providing specialized care, handling emergency cases, and engaging in research.
Hospitals are pivotal in the treatment of acid-related disorders, and their
increasing reliance on PPIs is a significant driver of market expansion. As
hospitals continue to advance their capabilities and treatments, the demand for
PPIs is expected to rise further.
Based on region, The Asia-Pacific region has emerged
as the fastest-growing segment in the global Proton Pump Inhibitors (PPIs)
market, and several key factors underpin this remarkable growth. This trend can
be attributed to the region's large and diverse population, increasing
prevalence of gastrointestinal disorders, economic development, and evolving
healthcare infrastructure. Here are the reasons behind the rapid expansion of
the PPI market in Asia-Pacific: The Asia-Pacific region has witnessed a rising
burden of gastrointestinal disorders, including gastroesophageal reflux disease
(GERD), peptic ulcers, and gastritis. These conditions are often managed with
PPIs, contributing to the increased demand for these medications. Changes in
dietary habits, stress levels, and sedentary lifestyles have led to an uptick
in acid-related disorders in the region. These factors drive the need for PPIs
to alleviate symptoms and promote healing. With the aging of the population,
the prevalence of acid-related disorders has increased. The elderly are more
susceptible to these conditions, and PPIs are commonly prescribed for their
management.
As economies in the Asia-Pacific region continue to
grow, there is greater access to healthcare services. This has led to increased
awareness, diagnosis, and treatment of gastrointestinal disorders, with PPIs
being a preferred choice for healthcare providers. Urbanization has brought
about lifestyle changes that contribute to the prevalence of acid-related
disorders. The concentration of healthcare facilities in urban areas has made
PPIs more accessible to the population. Many countries in Asia-Pacific are investing
in healthcare infrastructure development. This includes the expansion of
hospitals, clinics, and pharmacies, facilitating easier access to PPIs. Pharmaceutical
companies are actively seeking regulatory approvals for their PPI products in
the region. Simultaneously, marketing efforts and promotional activities are
creating awareness and driving PPI adoption.
Asia-Pacific region encompasses a diverse population,
including both high and low-income countries. This diversity presents a vast
market for PPIs, with varied healthcare needs. Emerging markets within the
Asia-Pacific region, such as China and India, offer significant growth
potential. These countries have witnessed substantial market entry and
expansion by pharmaceutical companies. In conclusion, the Asia-Pacific region's
rapid growth in the PPI market is a result of increased disease burden,
changing lifestyles, healthcare infrastructure development, and evolving
economic conditions. As awareness of gastrointestinal disorders continues to
rise and healthcare accessibility improves, the demand for PPIs is expected to
maintain its upward trajectory, making the region a key driver of global PPI
market expansion.
Major companies operating in Global Proton Pump
Inhibitors Market are:
- Bayer AG
- AstraZeneca PLC
- Pfizer, Inc
- Eli Lilly and Co Ltd
- Teva Pharmaceutical Industries Ltd
- Cadila Pharmaceuticals Ltd
- Janssen Pharmaceuticals Inc
- Takeda Pharmaceutical Co Ltd
- Eisai Co Ltd
Download Free Sample Report
Customers can also request 10% free customization on
this report
“The future of the global Proton Pump Inhibitors
(PPIs) market is poised for both challenges and opportunities. Here are some
key factors that will shape its trajectory: Over-the-counter PPIs will become
more prevalent, driven by the increasing prevalence of acid-related disorders
and consumer demand for self-medication options. PPIs will be increasingly used
in combination with other medications to address a spectrum of gastrointestinal
conditions, offering more comprehensive treatment solutions. Advances in drug
delivery systems and formulations will lead to more effective and targeted PPI
treatments, enhancing patient outcomes and adherence. The Asia-Pacific region
will be a focal point for market growth, with a rising population, expanding
healthcare infrastructure, and growing awareness of acid-related disorders. Evolving
regulations will influence the availability of PPIs, impacting prescription
requirements and OTC accessibility. The market will see increased competition
from generic PPI manufacturers, potentially driving down prices and increasing
affordability. Patient-centric care and personalized medicine will play a
pivotal role in the future PPI market, tailoring treatments to individual
needs. The global PPI market will continue to adapt to changing healthcare
landscapes and consumer preferences. While it faces challenges such as generic
competition and regulatory changes, it also holds promise in technological
advancements, broader accessibility, and personalized treatment options,
ensuring its relevance in the management of acid-related disorders.,” said Mr.
Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Proton Pump Inhibitors Market – Global
Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By
Drug Type (Pantoprazole; Omeprazole; Lansoprazole; Esomeprazole; Rabeprazole;
Dexlansoprazole; Other), By Disease Allocation (Ulcers, Gastroesophageal Reflux
Disease, Others), By Application (Hospitals, Clinic, Others), By Region,
Competition, 2019-2029F”, has evaluated the future growth potential of Global Proton Pump
Inhibitors Market and provides statistics & information on market size, structure,
and future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Proton Pump
Inhibitors Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com